Agile Therapeutics Inc. (NASDAQ:AGRX) shares saw unusually-high trading volume on Wednesday . Approximately 58,735 shares traded hands during trading, a decline of 9% from the previous session’s volume of 64,402 shares.The stock last traded at $6.65 and had previously closed at $6.58.

AGRX has been the subject of several recent research reports. FBR & Co reissued a “buy” rating and set a $17.00 target price on shares of Agile Therapeutics in a research note on Tuesday, May 10th. Zacks Investment Research upgraded shares of Agile Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Tuesday, May 10th. Cantor Fitzgerald restated a “buy” rating and set a $18.00 price target on shares of Agile Therapeutics in a report on Tuesday, May 10th. Finally, Noble Financial restated a “buy” rating and set a $15.00 price target on shares of Agile Therapeutics in a report on Friday, July 8th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $15.00.

The firm’s 50-day moving average is $7.44 and its 200-day moving average is $6.70. The company’s market cap is $195.45 million.

Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Monday, May 9th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.11. Equities research analysts expect that Agile Therapeutics Inc. will post ($1.12) earnings per share for the current year.

A hedge fund recently raised its stake in Agile Therapeutics stock. Marshall Wace LLP boosted its position in Agile Therapeutics Inc. (NASDAQ:AGRX) by 4.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 129,769 shares of the specialty pharmaceutical company’s stock after buying an additional 6,099 shares during the period. Marshall Wace LLP owned about 0.58% of Agile Therapeutics worth $1,267,000 as of its most recent SEC filing.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.